Browsing by Author "Loeffler, Jay"

Now showing items 1-8 of 8

    • AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients 

      Batchelor, Tracy Todd; Sorensen, A; di Tomaso, Emmanuelle; Zhang, Wei-Ting; Duda, Dan Gabriel; Cohen, Kenneth S.; Kozak, Kevin R.; Cahill, Daniel P.; Chen, Poe-Jou; Zhu, Mingwang; Ancukiewicz, Marek; Mrugala, Maciej M.; Plotkin, Scott Randall; Drappatz, Jan; Louis, David N.; Ivy, Percy; Scadden, David Thomas; Benner, Thomas; Loeffler, Jay Steven; Wen, Patrick Yung Chih; Jain, Rakesh K. (Elsevier BV, 2007)
      Using MRI techniques, we show here that normalization of tumor vessels in recurrent glioblastoma patients by daily administration of AZD2171—an oral tyrosine kinase inhibitor of VEGF receptors—has rapid onset, is prolonged ...

    • Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression 

      Sullivan, James P; Nahed, Brian Vala; Madden, M. W.; Oliveira, S. M.; Springer, S.; Bhere, Deepak; Chi, A. S.; Wakimoto, Hiroaki; Rothenberg, S. M.; Sequist, Lecia VanDam; Kapur, R.; Shah, Khalid A.; Iafrate, Anthony John; Curry, William Thomas; Loeffler, Jay Steven; Batchelor, Tracy Todd; Louis, David N.; Toner, Mehmet; Maheswaran, Shyamala; Haber, Daniel Arie (American Association for Cancer Research (AACR), 2014)
      Glioblastoma (GBM) is a highly aggressive brain cancer characterized by local invasion and angiogenic recruitment, yet metastatic dissemination is extremely rare. Here, we adapted a microfluidic device to deplete hematopoietic ...

    • Erlotinib for Progressive Vestibular Schwannoma in Neurofibromatosis 2 Patients 

      Plotkin, Scott Randall; Halpin, Chris; McKenna, Michael; Loeffler, Jay Steven; Batchelor, Tracy Todd; Barker, Frederick George (Ovid Technologies (Wolters Kluwer Health), 2010)
      In vitro treatment of Nf2-deficient cells with epidermal growth factor receptor (EGFR) inhibitors can inhibit cellular proliferation. We retrospectively assessed the effect of erlotinib (150 mg daily) on eleven consecutive ...

    • Improved Tumor Oxygenation and Survival in Glioblastoma Patients Who Show Increased Blood Perfusion After Cediranib and Chemoradiation 

      Batchelor, Tracy; Gerstner, Elizabeth; Emblem, Kyrre E.; Duda, Dan; Kalpathy-Cramer, Jayashree; Snuderl, Matija; Ancukiewicz, Marek; Polaskova, Pavlina; Pinho, Marco C.; Jennings, Dominique; Plotkin, Scott; Chi, Andrew S.; Eichler, April; Dietrich, Jorg; Hochberg, Fred H.; Lu-Emerson, Christine; Iafrate, Anthony; Ivy, S. Percy; Rosen, Bruce; Loeffler, Jay; Wen, Patrick; Sorenson, A. Greg; Jain, Rakesh (National Academy of Sciences, 2013-11-19)
      Antiangiogenic therapy has shown clear activity and improved survival benefit for certain tumor types. However, an incomplete understanding of the mechanisms of action of antiangiogenic agents has hindered optimization and ...

    • Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma 

      Batchelor, Tracy Todd; Duda, Dan Gabriel; di Tomaso, Emmanuelle; Ancukiewicz, Marek; Plotkin, Scott Randall; Gerstner, Elizabeth Robins; Eichler, April Fitzsimmons; Drappatz, Jan; Hochberg, Fred; Benner, Thomas; Louis, David N.; Cohen, Kenneth S.; Chea, Houng; Exarhopoulos, Alexis; Loeffler, Jay Steven; Moses, Marsha; Ivy, Percy; Sorensen, A; Wen, Patrick Yung Chih; Jain, Rakesh K. (American Society of Clinical Oncology (ASCO), 2010)
      Purpose Glioblastoma is an incurable solid tumor characterized by increased expression of vascular endothelial growth factor (VEGF). We performed a phase II study of cediranib in patients with recurrent glioblastoma. ...

    • Radiation Treatment for WHO Grade II and III Meningiomas 

      Walcott, Brian P.; Nahed, Brian V.; Brastianos, Priscilla K.; Loeffler, Jay S. (Frontiers Media S.A., 2013)
      The treatment of meningiomas is tailored to their histological grade. While World Health Organization (WHO) grade I lesions can be treated with either surgery or external beam radiation, WHO Grade II and III lesions often ...

    • A STAT3 Gene Expression Signature in Gliomas is Associated with a Poor Prognosis 

      Alvarez, James V.; Mukherjee, Neelanjan; Chakravarti, Arnab; Robe, Pierre; Zhai, Gary; Chakladar, Abhijit; Loeffler, Jay S; Black, Peter McLaren; Frank, David A. (Libertas Academica, 2007)
      Gliomas frequently display constitutive activation of the transcription factor STAT3, a protein that is known to be able to mediate neoplastic transformation. STAT3 regulates genes that play a central role in cellular ...

    • Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma 

      Plotkin, Scott Randall; Halpin, Chris; Blakeley, Jaishri O.; Slattery, William H.; Welling, Duane Bradley; Chang, Susan M.; Loeffler, Jay Steven; Harris, Gordon J.; Sorensen, A; McKenna, Michael John; Barker, Frederick George (Springer Nature, 2009)
      Neurofibromatosis type 2 (NF2) is a tumor suppressor gene syndrome characterized by multiple schwannomas, especially vestibular schwannomas (VS), and meningiomas. Anticancer drug trials are now being explored, but there ...